Formulations of tegavivint and related compounds
Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.
1. A composition consisting of:
a) particles of a compound of Formula I
wherein R A is hydrogen, R 7 and R 8 are independently selected from H and SO 2 NR 3 R 4 , wherein one of R 7 and R 8 is hydrogen and wherein NR 1 R 2 and NR 3 R 4 are independently 6-to 15-membered heterocycloalkyl containing one nitrogen in the ring, or a pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof,
b) a poloxamer surfactant;
c) sorbitol; and
d) water,
wherein the compound of Formula I and the poloxamer surfactant are provided in an aqueous suspension that is milled using roller milling or high energy milling until 90% of the particles are less than or equal to about 0.23 micrometers (μm) in diameter when measured using laser diffraction, and wherein the sorbitol is provided in an aqueous solution that is added thereto.
2. The composition of claim 1 , wherein the compound of Formula I is tegavivint or a pharmaceutically acceptable salt, ester, amide, stereoisomer or geometric isomer thereof.
3. The composition of claim 1 , wherein the composition is a nanoparticulate composition.
4. The composition of claim 1 , wherein the poloxamer surfactant is poloxamer 188.
5. The composition of claim 1 , wherein the concentration of the compound of Formula Lis between about 10 mg/ml and about 25 mg/ml.
6. The composition of claim 1 , wherein the concentration of the compound of Formula Lis about 25 mg/ml.
7. The composition of claim 1 , wherein the composition is formulated: (a) into a dosage form selected from the group consisting of tablets, and capsules; (b) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; (c) into a dosage form suitable for inhalation or parenteral administration; or (d) any combination of (a), (b), and (c).
8. The composition of claim 1 , wherein the composition exhibits long term stability.
9. The composition of claim 1 , wherein the compound of Formula I is tegavivint and the poloxamer surfactant is poloxamer 188.
10. The composition of claim 9 , wherein the concentration of tegavivint is about 25 mg/ml, the concentration of poloxamer 188 is about 0.625%(w/v), and the concentration of sorbitol is about 10%(w/v).
11. A method of preventing, treating or ameliorating cancer or tumor metastasis in a mammal in need thereof comprising administering to said mammal an effective amount of the composition of claim 1 .
12. A method for ameliorating cancer comprising administering to a subject in need thereof a combination of: 1) a pharmaceutically effective amount of the composition of claim 1 ; and 2) a pharmaceutically effective amount of at least one additional anti-cancer agent.
13. The method of claim 12 , wherein the additional anti-cancer agent is selected from the group consisting of antimitotic agents, antimetabolite agents, HDAC inhibitors, proteosome inhibitors, immunotherapeutic agents, FLT-3 EGFR, MEK, PI3K and other protein kinase inhibitors, LSD1 inhibitors, and WNT pathway inhibitors, alkylating agents and DNA repair pathway inhibitors, anti-hormonal agents, anti-cancer antibodies, and other cytotoxic chemotherapy agents.
14. A method of treating and/or preventing a fibrotic disease in a mammal in need thereof comprising administering to said mammal an effective amount of the composition of claim 1 .
15. The method of claim 14 , wherein the fibrotic disease is selected from the group consisting of pulmonary fibrosis, Dupuytren's contracture, scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, keloids, chronic kidney disease, chronic graft rejection, and other scarring/wound healing abnormalities, post-operative adhesions, reactive fibrosis.